Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 1
2014 4
2015 2
2016 5
2017 2
2018 9
2019 15
2020 8
2021 18
2022 12
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Aberrant lipid metabolism as a therapeutic target in liver cancer.
Pope ED 3rd, Kimbrough EO, Vemireddy LP, Surapaneni PK, Copland JA 3rd, Mody K. Pope ED 3rd, et al. Among authors: mody k. Expert Opin Ther Targets. 2019 Jun;23(6):473-483. doi: 10.1080/14728222.2019.1615883. Epub 2019 May 10. Expert Opin Ther Targets. 2019. PMID: 31076001 Free PMC article. Review.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B. Abou-Alfa GK, et al. Among authors: mody k. Future Oncol. 2023 Dec;19(38):2505-2516. doi: 10.2217/fon-2023-0486. Epub 2023 Sep 6. Future Oncol. 2023. PMID: 37671641 Free article. Review.
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Sonbol MB, et al. Among authors: mody k. JAMA Oncol. 2020 Dec 1;6(12):e204930. doi: 10.1001/jamaoncol.2020.4930. Epub 2020 Dec 10. JAMA Oncol. 2020. PMID: 33090186 Free PMC article.
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A. Wainberg ZA, et al. Among authors: mody k. Eur J Cancer. 2021 Jul;151:14-24. doi: 10.1016/j.ejca.2021.03.028. Epub 2021 May 4. Eur J Cancer. 2021. PMID: 33957442 Free article. Clinical Trial.
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.
Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, Jain A, De Armas AD, Reyes S, Le TM, Rahma OE, Stanton J, DeLeon TT, Roth M, Peters MLB, Zhu AX, Lennerz JK, Iafrate AJ, Boyhen K, VanCott C, Roberts LR, Lindsey S, Horick N, Goff LW, Mody K, Borad MJ, Shroff RT, Kelley RK, Javle MM, Goyal L. Spencer K, et al. Among authors: mody k. J Natl Cancer Inst. 2023 Jul 6;115(7):870-880. doi: 10.1093/jnci/djad046. J Natl Cancer Inst. 2023. PMID: 37040087 Free PMC article.
Antiangiogenic Therapy in Colorectal Cancer.
Mody K, Baldeo C, Bekaii-Saab T. Mody K, et al. Cancer J. 2018 Jul/Aug;24(4):165-170. doi: 10.1097/PPO.0000000000000328. Cancer J. 2018. PMID: 30119079 Review.
Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.
Sardar M, Recio-Boiles A, Mody K, Karime C, Chandana SR, Mahadevan D, Starr J, Jones J, Borad M, Babiker H. Sardar M, et al. Among authors: mody k. Expert Opin Pharmacother. 2022 Dec;23(18):2079-2089. doi: 10.1080/14656566.2022.2149322. Epub 2022 Nov 28. Expert Opin Pharmacother. 2022. PMID: 36394449 Review.
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Abou-Alfa GK, et al. Among authors: mody k. NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6. NEJM Evid. 2022. PMID: 38319892
Immune checkpoint inhibitor-related luminal GI adverse events.
Kröner PT, Mody K, Farraye FA. Kröner PT, et al. Among authors: mody k. Gastrointest Endosc. 2019 Dec;90(6):881-892. doi: 10.1016/j.gie.2019.09.009. Epub 2019 Sep 14. Gastrointest Endosc. 2019. PMID: 31526811 Review.
74 results